CN101455660A - Use of glaucocalyxin X in preparing anti-cancer medicine - Google Patents
Use of glaucocalyxin X in preparing anti-cancer medicine Download PDFInfo
- Publication number
- CN101455660A CN101455660A CNA200910044884XA CN200910044884A CN101455660A CN 101455660 A CN101455660 A CN 101455660A CN A200910044884X A CNA200910044884X A CN A200910044884XA CN 200910044884 A CN200910044884 A CN 200910044884A CN 101455660 A CN101455660 A CN 101455660A
- Authority
- CN
- China
- Prior art keywords
- glaucocalyxin
- cancer medicine
- ogen
- preparing anti
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to technical field of medicine, and relates to the use of diterperoid compound glaucocalyxin X in isodon japonica (Burm.f) Hara var.glaucocalyx (Maxim.) Hara in preparing anti-cancer medicine. The invention adopts an MTT method for executing cytotoxicity experiment. The result shows that the glaucocalyxin X equally has remarkable cytotoxicity and therefore can be used for preparing anti-cancer medicine. The invention provides a new source for preparing the anti-cancer medicine.
Description
Technical field
The present invention relates to medical technical field, is the purposes that blue calyx X-ogen is used to prepare cancer therapy drug.
Background technology
Blue calyx X-ogen (Glaucocalyxin X) is that the inventor separates noval chemical compound [the Zhao Bao Xiang (Xiang Zhaobao) that obtains from the herb of Labiatae Rabdosia plant Rabdosia japonica (Rabdosia japonica (Burm.f.) Hara var.glaucocalyx (Maxim.) Hara), Hai Sheng Chen (Chen Haisheng), et al.Two new diterpenoids from Rabdosiajaponica var.glaucocalyx, Chinese Chemical Letter 2008; 19:852-854].
The chemical constitution of blue calyx X-ogen is as follows:
So far do not see that relevant blue calyx X-ogen has the report of active anticancer.
Summary of the invention
The present invention provides a kind of purposes for preparing cancer therapy drug for blue calyx X-ogen.
The present invention adopts mtt assay, with A549 (human lung carcinoma cell), LOVO (people's colon-cancer cell), 6T-CEM (human T cell leukemia cell), HL-60 (human leukemia cell) cell strain blue calyx X-ogen has been carried out the cytotoxic activity experiment, experimental result finds that it has significant cytotoxic activity, therefore can be used for preparing cancer therapy drug.
The present invention provides a kind of new source for seeking cancer therapy drug.
The specific embodiment
Below by anticancer experiment in vitro, the present invention is described in detail.
The test of blue calyx X-ogen anti tumor activity in vitro
1, trial drug:
Blue calyx X-ogen separates from Rabdosia japonica and obtains, preparation method sees [Zhao BaoXiang (Xiang Zhaobao) for details, Hai Sheng Chen (Chen Haisheng), et al.Two new diterpenoidsfrom Rabdosia japonica var.glaucocalyx, Chinese Chemical Letter2008; 19:852-854].
Contrast medicine: doxycycline (DOX), the biochemical company limited in auspicious field, Shijiazhuang.
2, cell strain: provide by Shanghai Institute of Pharmaceutical Industry's Pharmacology Lab
1. A549 (human lung carcinoma cell); 2. LOVO (people's colon-cancer cell); 3. 6T-CEM (human T cell leukemia cell); 4. HL-60 (human leukemia cell)
3, culture fluid: RPMI1640+15%NBS+ is two anti-
4 other materials
Full-automatic microplate reader: model: (WellscanMK-2) production firm: Labsystems import 96 well culture plates etc.
5, experimental technique
Adopt mtt assay routinely, it is 4-5 * 10 that the every hole of 96 orifice plates adds concentration
4The cell suspension 100 μ l of individual/ml put 37 ℃, 5% CO
2In the incubator.Behind the 24h, add sample liquid, two multiple holes are established in 10 μ l/ holes, and 37 ℃, 5% CO
2Effect 72h.Every hole adds the MTT solution 20 μ l of 5mg/ml, adds lysate behind the effect 4h, and put in the incubator in 100 μ l/ holes, and 570nm OD value is surveyed with the full-automatic microplate reader of MK-2 in the dissolving back.
6, experimental result: the results are shown in Table 1.
The blue calyx X-ogen of table 1 monomer is to the in-vitro multiplication inhibitory action of human body tumour cell
By table 1 as seen, blue calyx X-ogen has very strong inhibitory action to the test tumor cell.Therefore can be used for preparing cancer therapy drug.
Claims (1)
1, the application of blue calyx X-ogen in the preparation cancer therapy drug,
Its chemical constitution is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910044884XA CN101455660B (en) | 2009-01-05 | 2009-01-05 | Use of glaucocalyxin X in preparing anti-cancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910044884XA CN101455660B (en) | 2009-01-05 | 2009-01-05 | Use of glaucocalyxin X in preparing anti-cancer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101455660A true CN101455660A (en) | 2009-06-17 |
| CN101455660B CN101455660B (en) | 2010-08-11 |
Family
ID=40766958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910044884XA Expired - Fee Related CN101455660B (en) | 2009-01-05 | 2009-01-05 | Use of glaucocalyxin X in preparing anti-cancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101455660B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102584780A (en) * | 2012-01-16 | 2012-07-18 | 新乡医学院 | Glaucocalyxin derivative as well as preparing method and application thereof |
| CN109651331A (en) * | 2019-01-02 | 2019-04-19 | 中国人民解放军军事科学院军事医学研究院 | A kind of glaucocalyxin A derivative and its preparation method and application |
-
2009
- 2009-01-05 CN CN200910044884XA patent/CN101455660B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102584780A (en) * | 2012-01-16 | 2012-07-18 | 新乡医学院 | Glaucocalyxin derivative as well as preparing method and application thereof |
| CN109651331A (en) * | 2019-01-02 | 2019-04-19 | 中国人民解放军军事科学院军事医学研究院 | A kind of glaucocalyxin A derivative and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101455660B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101455652B (en) | Use of diterpenoids from Isodon japonica var.galaucocalyx in preparing anti-cancer medicine | |
| CN101455660B (en) | Use of glaucocalyxin X in preparing anti-cancer medicine | |
| CN102247357B (en) | Application of uvarilactam and aristololactam BI in preparation of anticancer medicaments | |
| Chui et al. | Gleditsia sinensis fruit extract-induced apoptosis involves changes of reactive oxygen species level, mitochondrial membrane depolarization and caspase 3 activation | |
| CN101797247B (en) | Application of isoflavone compound in preparation of anti-tumor drug or food | |
| CN103356736A (en) | Dyetree fruit polyphenol extract with antineoplastic effect and preparation method thereof | |
| CN103800314A (en) | Application of glaucocalyxin L in pharmacy | |
| CN101525323B (en) | Novel styryl chromone type compound and preparation method and use thereof | |
| CN103638052A (en) | Polyrhachis dives extractive, and preparation and medical purpose thereof | |
| Lee et al. | Anti-cancer Activities of Ginseng Extract Fermented with Phettinus linteus | |
| CN108796022A (en) | The preparation method and application of Saikogenin A and D | |
| CN102218047A (en) | Medicament for treating drug-resistant bacteria infection, and application of active ingredient thereof in pharmacy | |
| CN103784429A (en) | Application of glaucocalyxin K in preparing anticancer drugs | |
| CN103638055B (en) | Polyhachis vicina Roger extract and and antifungal pharmaceutical purposes thereof | |
| CN101156841B (en) | An antineoplastic new use of biphenyl acetic acid and its salt | |
| CN102293765B (en) | Application of isoflavone compound to preparation of antitumor medicines or food | |
| CN102293778B (en) | Application of isoflavone compound to preparation of antitumor medicines or food | |
| CN106177035B (en) | Preparation method and application of effective rosa chinensis flower extract with blood sugar reducing and anticancer functions | |
| CN106176764B (en) | 2a in Isodon excisoides, 3 β, -12 alkene -28- ursolic acid application in preparations of anti-tumor drugs of 19a- trihydroxies | |
| Zhi-Peng et al. | Cytotoxic activity of five limonoids from Meliae cortex and their structure-activity relationship | |
| CN104447655A (en) | Novel sesquiterpene coumarins in ferula sinkiangensis K.M.Shen as well as preparation methods and medical applications of novel sesquiterpene coumarins | |
| CA2588959A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| CN113368090B (en) | Application of 3, 4-seco cycloartenane type tetracyclic triterpene compound or pharmaceutically acceptable salt thereof in preparation of anticancer drugs | |
| CN111334536B (en) | Preparation method of compound diaporisoindole A and application of compound diaporisoindole A in preparation of antitumor drugs | |
| CN102309479A (en) | Application of isoflavone compound in preparation of medicaments or foods for resisting tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20150105 |
|
| EXPY | Termination of patent right or utility model |